Endoscopic Weight-Loss Procedures: ESG and Gastric Balloons

Where endoscopic treatments sit

Endoscopic bariatric therapies fill the gap between medication and surgery. They are done through a flexible scope passed through the mouth — no incisions, no rerouting, usually outpatient — so they are less invasive than an operation. They are also less powerful, and some are temporary. They are a genuine middle option for a specific patient, not a replacement for surgery and not a magic bullet.

The two categories that matter are endoscopic sleeve gastroplasty (ESG) and intragastric balloons. We treat them as we treat everything: match the tool to the goal, and be honest about effect size and durability. → The W8Experts Clinical Approach

Endoscopic sleeve gastroplasty (ESG)

What it is: an endoscopist places a series of sutures inside the stomach to fold and shrink it into a tube-like shape, reducing volume and slowing emptying — no part of the stomach is removed and nothing is rerouted. It's often called an "incisionless sleeve," though it is not the same as a surgical sleeve gastrectomy.

• Weight loss: middle-ground — less than surgical sleeve gastrectomy or bypass, more than most balloons. A randomised trial (MERIT) supports meaningful weight loss versus lifestyle alone; state qualitatively — [verify] exact percentages.
• Invasiveness: no incisions, typically outpatient, faster recovery than surgery.
• Reversibility: no organ removed, but it is not simply undone; considered semi-durable rather than easily reversible.
• Durability: better than balloons; sutures can loosen over time, and results still depend on sustained behaviour change.
• Risks: generally lower than surgery — bleeding, pain, nausea; serious complications (leak, collection, bleeding needing intervention) are uncommon but possible.

ESG is the more substantial of the two endoscopic options and the closer analogue to surgery, at lower efficacy and lower risk. Grade B 🟡

Intragastric balloons

What it is: a soft balloon is placed in the stomach (endoscopically or, for some, swallowed as a capsule) and filled with saline or gas, taking up space and promoting fullness. It is temporary — most are removed after about 6 months.

• Weight loss: smaller than ESG, and largely temporary — a substantial portion is commonly regained after removal unless lifestyle change is sustained.
• Invasiveness: minimal; often no incision and sometimes no sedation for swallowable types.
• Reversibility: fully reversible by design — it comes out.
• Durability: the core limitation. The balloon buys a window; keeping the loss depends entirely on what happens during and after it.
• Risks: nausea and vomiting are very common early; less commonly, ulceration, balloon deflation/migration, and — rarely — obstruction or perforation. Regulators have noted rare serious events, so device selection and monitoring matter.

Balloons are best understood as a temporary kickstart, not a standalone solution. Grade B 🟡 / C 🟠 (durability limited).

Efficacy — the honest ranking

Applying our weight-loss-figure discipline (procedure, not a single headline number), the average effect sizes rank cleanly:

Bariatric surgery (~25–30% total) > ESG > intragastric balloon > lifestyle alone.

And against medication, the comparison is now genuinely close: potent GLP-1/GIP drugs (tirzepatide ~15–20.9% treatment-policy in SURMOUNT-1; semaglutide ~15% in STEP 1) produce weight loss that overlaps with or exceeds ESG, without any procedure. That reshapes the whole conversation below. All figures are averages that vary by person, and all endoscopic results depend on sustained lifestyle change. Grade B 🟡 → Semaglutide · Tirzepatide

Durability — the make-or-break question

The defining feature of endoscopic therapy is durability, and it differs sharply between the two:

• Balloons are temporary and their weight loss is largely temporary — regain after removal is common without sustained behaviour change.
• ESG is more durable than a balloon but less durable than surgery; sutures can loosen, and long-term maintenance still rests on lifestyle.

Neither overrides the body's tendency to defend its weight. The window an endoscopic procedure creates is only as valuable as the maintenance plan built around it — which is why we plan maintenance before starting, not after. → Weight Regain & Maintenance

Endoscopic vs surgery

EVIDENCE CARD · Endoscopic therapy vs bariatric surgery

• WHAT'S SHOWN: Endoscopic procedures (especially ESG) produce meaningful but smaller weight loss than surgery, with lower invasiveness and lower complication risk. Surgery produces the largest average loss (~25–30%) and the strongest diabetes-remission and long-term outcome data.
• WHAT'S UNKNOWN: Long-term durability of ESG versus surgery over many years; comparative metabolic/diabetes outcomes; the best role alongside medication.
• OUR POSITION: Endoscopic therapy is a reasonable middle option for patients who want something less invasive than surgery, don't qualify for or don't want an operation, or need a bridge — but it should be chosen understanding it is less powerful and, for balloons, largely temporary. It does not carry surgery's diabetes-remission or mortality evidence. Grade B 🟡

Endoscopic vs medication

This comparison has shifted the fastest. A few years ago, an endoscopic procedure clearly out-lost available drugs. Now:

• Potent GLP-1/GIP medications produce weight loss that overlaps ESG and exceeds balloons, with no procedure and no sedation.
• Semaglutide carries a cardiovascular-outcome benefit (SELECT, ~20% MACE reduction) that endoscopic therapy has no equivalent for.
• But medication generally requires ongoing use — stopping usually brings regain (STEP 1 extension: ~⅔ regained within ~1 year) — whereas an endoscopic procedure is a discrete intervention.
• The two can be combined: a procedure plus medication, or medication after a balloon, are legitimate strategies.

So "procedure or drug" is rarely a clean either/or. It depends on preferences, whether ongoing medication is acceptable, cost and access, and the specific goal. Grade B 🟡 → GLP-1 & Incretin Medications

Who might consider endoscopic treatment

Reasonable candidates often include people who:

• Have obesity but don't qualify for, or don't want, bariatric surgery.
• Want a less invasive, reversible or semi-durable option.
• Need a bridge — for example, to reduce surgical risk before another procedure.
• Understand and accept that the effect is smaller than surgery and, for balloons, largely temporary.

As with every option, candidacy is a clinical conversation grounded in the person's health goals, not BMI alone. → How Obesity Should Be Evaluated · BMI, Body Fat & Body Composition

What endoscopic treatments don't do

• They don't match surgery's weight loss or its diabetes-remission and mortality evidence.
• Balloons don't produce lasting loss on their own — they're a temporary window.
• They don't remove the need for lifestyle change — sustained behaviour is what holds any result.
• They don't fix the biology of weight regain — the body still defends its weight. → Weight Regain & Maintenance

SIGNATURE — "What the evidence says: endoscopic obesity treatment"

• What we know: ESG produces meaningful, middle-ground weight loss with low invasiveness; balloons produce smaller, largely temporary loss. Both are safer and weaker than surgery.
• What we think: Endoscopic therapy is a genuine option for the right patient — less invasive than surgery, more substantial than lifestyle alone — but its value hinges on the maintenance plan and, increasingly, on how it's combined with medication.
• What we don't know: Long-term durability of ESG versus surgery, comparative metabolic outcomes, and the optimal role alongside GLP-1 drugs.
• What patients should do: Consider it as a middle option matched to goals and preferences, understand it's less powerful than surgery and (for balloons) temporary, and plan maintenance before starting.

Questions patients ask

KEEP READING

• Bariatric Surgery — the more powerful option, with the strongest diabetes and mortality evidence.
• GLP-1 & Incretin Medications — non-surgical treatment that now overlaps endoscopic weight loss.
• Weight Regain & Maintenance — why durability, not the procedure, decides the outcome.
• Fatty Liver & Weight Loss — how any sustained weight loss affects the liver.

Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: 2026-08-10 · References: ASGE/ASMBS guidance on endoscopic bariatric therapies; randomised and prospective data on endoscopic sleeve gastroplasty (e.g. MERIT) and intragastric balloons; SURMOUNT and STEP programs for medication comparison. Effect sizes stated qualitatively where exact figures require re-verification. Educational only; not individualized medical advice.